XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Collaboration and Licensing Agreements (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Sep. 30, 2015 USD ($) item | Jul. 31, 2013 USD ($) item | May. 31, 2013 USD ($) item | Mar. 31, 2013 USD ($) item | Jan. 31, 2013 USD ($) item | Feb. 28, 2009 USD ($) item | Sep. 30, 2015 USD ($) item | Sep. 30, 2014 USD ($) | Mar. 31, 2014 USD ($) | Sep. 30, 2015 USD ($) item | Sep. 30, 2014 USD ($) | Dec. 31, 2014 USD ($) employee | Dec. 31, 2010 USD ($)
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | $ 3,503,000 | $ 848,000 |  | $ 6,008,000 | $ 3,856,000 |  |
Current portion of deferred revenue | $ 47,652,000 |  |  |  |  |  | 47,652,000 |  |  | 47,652,000 |  | $ 2,254,000 |
Collaboration and Option Agreement | Amgen, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Option term after delivery of the data from a Phase 2 proof-of-concept (POC) clinical trial |  |  |  |  |  |  |  |  |  |  |  |  | 90 days
Nonrefundable upfront payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 11,000,000
Milestone payment received |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  | 600,000 |  | 0 | 1,700,000 |  |
Deferred revenue | 0 |  |  |  |  |  | 0 |  |  | 0 |  |  |
Option fee |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000
License Agreement | Merck Sharp & Dohme Corp. |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fees |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |
Milestone payment received |  |  |  |  |  |  |  |  | $ 500,000 |  |  |  |
Revenue recognized |  |  |  |  |  |  | 25,000 | 25,000 |  | 75,000 | 500,000 |  |
Deferred revenue | 75,000 |  |  |  |  |  | 75,000 |  |  | 75,000 |  |  |
Number of compounds | item |  | 1 |  |  |  |  |  |  |  |  |  |  |
Portion of nonrefundable upfront payment allocated to option |  | $ 0 |  |  |  |  |  |  |  |  |  |  |
License Agreement | Alexion Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  | 2,500,000 |  |  |
Option and license agreement | Alexion Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  | 3,000,000 |  |  |  |  |  |  |  |
Annual maintenance fees |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 300,000 | 200,000 |  | 1,300,000 | 800,000 |  |
Deferred revenue | 1,300,000 |  |  |  |  |  | 1,300,000 |  |  | 1,300,000 |  |  |
Number of different target programs | item |  |  |  |  | 6 |  |  |  |  |  |  |  |
Research license term |  |  |  |  | 5 years |  |  |  |  |  |  |  |
Additional research term |  |  |  |  | 3 years |  |  |  |  |  |  |  |
Extension fee |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  |
Annual maintenance fees payable during any extension of research term |  |  |  |  | 1,000,000 |  |  |  |  |  |  |  |
Option fee |  |  |  |  | $ 4,000,000 |  |  |  |  |  |  |  |
Research term of revenue recognized |  |  |  |  | 5 years |  |  |  |  |  |  |  |
2009 Research License and Commercialization Agreement | CSL Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  | $ 750,000 |  |  |  |  |  |  |
Research license term |  |  |  |  |  | 5 years |  |  |  |  |  |  |
2009 Research License and Commercialization Agreement | CSL Limited | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Number of commercial options | item |  |  |  |  |  | 5 |  |  |  |  |  |  |
May 2013 Research License and Commercialization Agreement | CSL Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  | $ 2,500,000 |  |  |  |  |  |  |  |  |  |
Milestone payment received |  |  |  |  |  |  |  |  |  | 2,500,000 |  |  |
Revenue recognized |  |  |  |  |  |  |  | 0 |  |  | 700,000 |  |
Deferred revenue | 0 |  |  |  |  |  | 0 |  |  | 0 |  |  |
Number of commercial options | item |  |  | 4 |  |  |  |  |  |  |  |  |  |
March 2013 License Agreement | CSL Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 0 | $ 0 |  | 0 | $ 0 |  |
Deferred revenue | 0 |  |  |  |  |  | 0 |  |  | 0 |  |  |
Number of compounds | item |  |  |  | 1 |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novo Nordisk |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  |  |  |  |  | 2,500,000 |
Potential milestone payment |  |  |  |  |  |  |  |  |  |  |  | $ 2,000,000 |
Revenue recognized |  |  |  |  |  |  | 700,000 |  |  | 2,100,000 |  |  |
Deferred revenue | 1,900,000 |  |  |  |  |  | 1,900,000 |  |  | $ 1,900,000 |  |  |
Research license term |  |  |  |  |  |  |  |  |  |  |  | 2 years |
Additional research term |  |  |  |  |  |  |  |  |  |  |  | 12 months |
Research funding |  |  |  |  |  |  |  |  |  |  |  | $ 1,600,000 |
Number of full time employees that will be given research support | employee |  |  |  |  |  |  |  |  |  |  |  | 4 |
Research term of revenue recognized |  |  |  |  |  |  |  |  |  | 2 years |  |  |
Research and License Agreement 2015 | Amgen, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment | 45,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment | 1,700,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 0 |  |  | $ 0 |  |  |
Deferred revenue | $ 45,000,000 |  |  |  |  |  | $ 45,000,000 |  |  | $ 45,000,000 |  |  |
Number of different target programs | item | 6 |  |  |  |  |  |  |  |  |  |  |  |
Number of previously indentified products | item | 3 |  |  |  |  |  | 3 |  |  | 3 |  |  |
Research and License Agreement 2015 | Amgen, Inc. | CD38 Program |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  |  |  | $ 13,750,000 |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 355,000,000 |  |  |
Research and License Agreement 2015 | Amgen, Inc. | Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  |  |  | 6,250,000 |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | $ 260,500,000 |  |  |
Research license term |  |  |  |  |  |  |  |  |  | 3 years |  |  |
Additional research term |  |  |  |  |  |  |  |  |  | 1 year |  |  |
Previous targets which bispecific technology will be applied | item | 5 |  |  |  |  |  | 5 |  |  | 5 |  |  |
Development-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | $ 55,000,000 |  |  |
Development-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 35,500,000 |  |  |
Regulatory-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 70,000,000 |  |  |
Regulatory-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 55,000,000 |  |  |
Sales-based | Research and License Agreement 2015 | Amgen, Inc. | CD38 Program |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 230,000,000 |  |  |
Sales-based | Research and License Agreement 2015 | Amgen, Inc. | Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | $ 170,000,000 |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the revenue earned during the period pertaining to collaborations, licenses and milestones. + References No definition available. + Details
Name: | xncr_CollaborationsLicensesAndMilestonesRevenue
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the additional period for which research term may be extended under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementAdditionalResearchTerm
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of nonrefundable upfront fees as provided under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementAnnualMaintenanceFees
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of annual maintenance fees payable during any extension of research term under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementAnnualMaintenanceFeesDuringExtensionOfResearchTerm
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of extension fees for extension of research term under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementExtensionFee
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payment received under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementMilestonePayment
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of nonrefundable upfront fee allocated to option under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNonrefundableUpfrontFeeAllocatedToOption
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of nonrefundable upfront fees as provided under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNonrefundableUpfrontFees
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of commercial options provided under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfCommercialOptions
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of compounds. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfCompounds
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of different target programs under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfTargetPrograms
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of option fee that must be paid by counterparty with respect to each target for which the option is exercised as per the terms of the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementOptionFee
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the option term expiring after delivery of the data from a Phase 2 proof-of-concept clinical trial under a collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementOptionTermAfterDeliveryOfDataFromPhase2ProofOfConceptClinicalTrial
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of research funding. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementResearchFunding
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the research license term under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementResearchLicenseTerm
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of full time employees that will be given research support + References No definition available. + Details
Name: | xncr_NumberOfFullTimeEmployeesInWhichResearchSupportWillBeProvided
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents information pertaining to the previously indentified programs that can be substitutued during the research term provided Amgen has not initiated non human primate studies + References No definition available. + Details
Name: | xncr_NumberOfPreviousIndentifiedProductsInWhichSubstitutionCanOccur
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents informaton in which bispecific technology will be applied to previous targets + References No definition available. + Details
Name: | xncr_PreviousTargetsWhichBispecificTechnologyWillBeApplied
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period over which revenue is recognized under the agreement + References No definition available. + Details
Name: | xncr_RevenueRecognitionContractPeriod
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties. + References No definition available. + Details
Name: | xncr_RevenueRecognitionMilestoneMethodPending
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_CollaborationAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_MerckSharpAndDohmeCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_OptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchLicenseAndCommercialization2009AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_CSLLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_May2013ResearchLicenseAndCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_March2013LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_NovoNordiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchAndLicenseAgreement2015Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_Cd38ProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_DiscoveryProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_DevelopmentBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_RegulatoryBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_SalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |